William H. Bradley

8.3k total citations
78 papers, 1.0k citations indexed

About

William H. Bradley is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, William H. Bradley has authored 78 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Reproductive Medicine, 25 papers in Oncology and 20 papers in Obstetrics and Gynecology. Recurrent topics in William H. Bradley's work include Ovarian cancer diagnosis and treatment (40 papers), Endometrial and Cervical Cancer Treatments (15 papers) and PARP inhibition in cancer therapy (14 papers). William H. Bradley is often cited by papers focused on Ovarian cancer diagnosis and treatment (40 papers), Endometrial and Cervical Cancer Treatments (15 papers) and PARP inhibition in cancer therapy (14 papers). William H. Bradley collaborates with scholars based in United States, Spain and France. William H. Bradley's co-authors include Peter A. Argenta, A. W. Downie, Kevin R. McCarthy, David E. Cohn, Melissa A. Geller, Charles A. Leath, Janet S. Rader, Matthew Boente, Levi S. Downs and Doris Brooker and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Oncogene.

In The Last Decade

William H. Bradley

71 papers receiving 959 citations

Peers

Countries citing papers authored by William H. Bradley

Since Specialization

Citations

This map shows the geographic impact of William H. Bradley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William H. Bradley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William H. Bradley more than expected).

Fields of papers citing papers by William H. Bradley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William H. Bradley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William H. Bradley. The network helps show where William H. Bradley may publish in the future.

Co-authorship network of co-authors of William H. Bradley

This figure shows the co-authorship network connecting the top 25 collaborators of William H. Bradley. A scholar is included among the top collaborators of William H. Bradley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William H. Bradley. William H. Bradley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer 2024 ·Cancer ·David G. Mutch, Athina Voulgari, Xian Chen, William H. Bradley, Ana Oaknin, José Alejandro Pérez Fidalgo, (unknown), Antonio Casado, Robert W. Holloway, Matthew A. Powell, Małgorzata Nowicka, Gabriele Schaefer, Mark Merchant, Yibing Yan	2
2	LBA29 Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012 2024 ·Annals of Oncology ·(unknown), Bhavana Pothuri, M.P. Barretina Ginesta, Whitney A. Spannuth Graybill, (unknown), C Mccormick, Mansoor R. Mirza, R. G. Moore, (unknown), (unknown), Gilles Freyer, David M. O’Malley, Florian Heitz, Mark S. Shahin, Ilan Bruchim, William H. Bradley, Natalie Compton, Izabela A. Malinowska, Andrés Redondo, (unknown)	2
3	Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial 2023 ·JCO Clinical Cancer Informatics ·Xiang Yin, (unknown), Elizabeth B. Lamont, Premal H. Thaker, William H. Bradley, Charles A. Leath, Kathleen N. Moore, Khursheed Anwer, (unknown), Nicholas Borys	7
4	PO13 2023 ·Brachytherapy ·(unknown), (unknown), (unknown), (unknown), (unknown), Erin Bishop, (unknown), William H. Bradley, Denise Uyar, Janet S. Rader, Meena Bedi, Bradley A. Erickson	1
5	GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study 2021 ·Clinical Cancer Research ·Premal H. Thaker, William H. Bradley, Charles A. Leath, (unknown), Nicholas Borys, Khursheed Anwer, (unknown), Junko Matsuzaki, Wiam Bshara, Kunle Odunsi, Ronald D. Alvarez	19
6	818P Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in the VELIA study 2020 ·Annals of Oncology ·Aikou Okamoto, Gini F. Fleming, Michael A. Bookman, Mark F. Brady, Elizabeth M. Swisher, Karina Dahl Steffensen, Noelle Cloven, Takayuki Enomoto, David M. O’Malley, Linda Van Le, Krishnansu S. Tewari, Joyce N. Barlin, William H. Bradley, Kathleen N. Moore, John K. Chan, Meijing Wu, (unknown), Minh H. Dinh, Robert L. Coleman, Carol Aghajanian	2
7	811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1 2020 ·Annals of Oncology ·Susana Banerjee, Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, (unknown), Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Eileen Holmes, Elizabeth Lowe, Paul DiSilvestro	47
8	Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial 2018 ·Annals of Oncology ·Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, (unknown), Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro	7
9	A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study 2017 ·Gynecologic Oncology ·Premal H. Thaker, William E. Brady, Heather A. Lankes, Kunle Odunsi, William H. Bradley, Kathleen N. Moore, Carolyn Y. Muller, Khursheed Anwer, Russell J. Schilder, Ronald D. Alvarez, Paula M. Fracasso	49
10	Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study 2017 ·Gynecologic Oncology ·David E. Cohn, Michael W. Sill, Joan L. Walker, David M. O’Malley, Christa Nagel, Teresa Rutledge, William H. Bradley, Debra L. Richardson, Katherine Moxley, Carol Aghajanian	61
11	Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study 2017 ·Gynecologic Oncology ·Vivian E. von Gruenigen, Helen Huang, Jan H. Beumer, Heather A. Lankes, William P. Tew, Thomas J. Herzog, Arti Hurria, Robert S. Mannel, Tina Rizack, Lisa M. Landrum, Peter G. Rose, Ritu Salani, William H. Bradley, Thomas Rutherford, Robert V. Higgins, Angeles Alvarez Secord, Gini F. Fleming	53
12	Pediatric Gynecologic Cancers 2017 ·Current Oncology Reports ·Lauren Pommert, William H. Bradley	17
13	IPI59: An Actionable Biomarker to Improve Treatment Response in Serous Ovarian Carcinoma Patients 2016 ·Statistics in Biosciences ·Ji Suk Choi, (unknown), Kevin H. Eng, Keegan Korthauer, William H. Bradley, Janet S. Rader, Christina Kendziorski	3
14	3-T MRI-based adaptive brachytherapy for cervix cancer: Treatment technique and initial clinical outcomes 2014 ·Brachytherapy ·Jordan Kharofa, Natalya Morrow, Tracy Kelly, Jason Rownd, E.S. Paulson, Janet S. Rader, Denise Uyar, William H. Bradley, Beth Erickson	25
15	New techniques in radical hysterectomy 2008 ·Current Opinion in Obstetrics & Gynecology ·Konstantin Zakashansky, William H. Bradley, Farr Nezhat	24
16	Paraneoplastic cerebellar degeneration in ovarian carcinoma: case report with review of immune modulation 2008 ·International Journal of Gynecological Cancer ·William H. Bradley, Peter R. Dottino, Jamal Rahaman	15
17	Endometrial carcinoma expresses an increased cathepsin B/D ratio 2007 ·Gynecologic Oncology ·William H. Bradley, (unknown), Lisa Rodgers, Charles H. Blomquist, Levi S. Downs	8
18	Hysteroscopy and Cytology in Endometrial Cancer 2004 ·Obstetrics and Gynecology ·William H. Bradley, Matthew Boente, Doris Brooker, Peter A. Argenta, Levi S. Downs, Patricia L. Judson, Linda F. Carson	45
19	Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression 2004 ·Gynecologic Oncology ·Melissa A. Geller, Peter A. Argenta, William H. Bradley, Kathryn E. Dusenbery, Doris Brooker, Levi S. Downs, Patricia L. Judson, Linda F. Carson, Matthew Boente	47
20	Report of research conference on middle ear effusions 1976 ·Annals of Otology Rhinology & Laryngology ·David Lim, William H. Bradley, (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact